Parties on both sides are increasing the pressure on Trump to make a decision on marijuana, because upcoming Supreme Court decisions could be a catalyst.
In his first statement to the public on the cannabis Rescheduling Process, Trump said that the government will decide whether or not cannabis should be classified as Schedule III, which could have significant benefits for industry.
As the excitement around the cannabis industry continues to grow, and stocks continue to retain their majority of value, despite the spike in the stock market following the recent news reports, other political groups have decided that they want a piece of the action.
The Drug Policy Alliance, a leading pro-cannabis policy group, has started a campaign to urge the President to do more than just reschedule cannabis, and instead, declassify it, and remove it from the Controlled Substances Act.
They have now launched a petition calling for equity-focused reform, including the expungement of past convictions, reinvestment in communities, and stating clearly that rescheduling would continue to criminalise citizens, and that ‘anything less than descheduling falls short’.
The hardline antidrug group Smart Approaches to Marijuana, along with a coalition consisting of religious and law enforcement groups, announced their efforts to influence the administration to the contrary and to keep cannabis on Schedule 1.
In a letter signed by organisations including the Drug Enforcement Association of Federal Narcotics Agents, the Family Research Council, and the National Narcotic Officers’ Associations’ Coalition, the groups warned that rescheduling would provide a ‘$2 billion tax break’ to dispensaries and illicit operators, undermine workplace drug testing, and send ‘the wrong message’ to youth.
These groups have also rejected the conclusion of a Department of Health and Human Services (HHS) review conducted under Biden’s administration which concluded that cannabis had accepted medical use and should not be put on Schedule III.
Two separate US Supreme Court marijuana cases that each have the potential to change cannabis laws are getting closer to hearing.
In the first instance, US vs Hemani Concerns whether the federal law that prohibits anyone who uses controlled drugs from owning a gun applies to marijuana consumers.
The lower court decided that the law could not be applied to prosecute the Texas man, who had been a frequent cannabis consumer but was not drunk when FBI agents discovered a gun in his house.
Defense attorneys have warned that millions of Americans, who consume marijuana legally under state laws, could be charged with felony offenses if the Supreme Court rules in favor of the ban.
Elsewhere, Canna Provisions and Bondi Cannabis operators from Massachusetts and Verano Holdings, a multi-state cannabis operator, filed the petition.
It challenges the Controlled Substances Act, arguing that Congress lacks the power to criminalize the possession, cultivation or sale of marijuana that is conducted entirely in one state.
This case is a review of the Court’s ruling from 2005. Gonzales v. RaichIn a decision, the Supreme Court of Canada upheld the federal authority over cannabis grown within state borders. Plaintiffs assert that since the ruling, conditions have significantly changed, as state-level legalisation has reduced, not increased, illicit interstate marijuana markets.
Court decisions may help to paint a more accurate picture of Trump Administration’s inconsistency and fractured position when it comes to cannabis reform.
On 6 October, the next session of the Court will begin. The court hasn’t yet decided whether to hear the case.
Parties on both sides are increasing the pressure on Trump to make a decision on marijuana, because upcoming Supreme Court decisions could be a catalyst.
In his first statement to the public on the cannabis Rescheduling Process, Trump said that the government will decide whether or not cannabis should be classified as Schedule III, which could have significant benefits for industry.
The fervent enthusiasm surrounding cannabis continues, with stocks retaining the majority of their value after spiking in response to the news. Various political and lobbying organizations are now joining the fray.
Drug Policy Alliance has a new anti-cannabis campaign, urging President Obama to move beyond rescheduling and declassifying cannabis from the Controlled Substances Act.
They have now launched a petition calling for equity-focused reform, including the expungement of past convictions, reinvestment in communities, and stating clearly that rescheduling would continue to criminalise citizens, and that ‘anything less than descheduling falls short’.
Smart Approaches to Marijuana – a hard-line antidrug organization backed by a coalition including law enforcement agencies and religious organizations – announced that they were also working to convince the government to change its mind and to maintain cannabis as Schedule 1 drug.
In a letter signed by organisations including the Drug Enforcement Association of Federal Narcotics Agents, the Family Research Council, and the National Narcotic Officers’ Associations’ Coalition, the groups warned that rescheduling would provide a ‘$2 billion tax break’ to dispensaries and illicit operators, undermine workplace drug testing, and send ‘the wrong message’ to youth.
They also reject the findings of the Department of Health and Human Services under Biden’s administration that marijuana has medical applications and should be placed on Schedule III.
Two separate US Supreme Court marijuana cases that each have the potential to change cannabis laws are getting closer to hearing.
In the first instance, US vs Hemani Cannabis consumers are concerned about whether the federal prohibition on firearm possession by anyone using controlled substances applies to them.
An appeals court in Texas ruled the statute couldn’t be used against a man who had been a cannabis consumer for years but wasn’t drunk at the time FBI agents discovered the firearm.
US Department of Justice has filed an appeal, arguing long-standing precedent permits legislatures to disarm drug addicts. Defence attorneys, however, warn that millions of Americans could face criminal charges for lawfully consuming cannabis in accordance with state law if Supreme Court affirms ban.
Elsewhere, Canna Provisions and Bondi Cannabis operators from Massachusetts and Verano Holdings, a multi-state cannabis operator, filed a petition.
The Controlled Substances Act is challenged on the basis that Congress does not have the authority to criminalise cannabis cultivation, possession or sales that occur entirely in a single State.
This case is a review of the Court’s ruling from 2005. Gonzales v. RaichIn a decision, the Supreme Court of Canada upheld the federal authority over cannabis grown within state borders. The plaintiffs claim that the situation has changed dramatically since, and state-level cannabis legalisation is reducing rather than increasing illicit interstate markets.
Court decisions may help to paint a more accurate picture of Trump Administration’s inconsistency and fractured approach on marijuana reform, at an important time.
On 6 October, the next session of the Court will begin. The Court has yet to announce whether or not it will be hearing either case.
Cannabis Law Resources Available in Poland
Discover essential legal information about the cultivation of cannabis, its sale, and regulations governing medical products in Poland. These guides will help you understand the legal requirements, such as certifications, permits, and compliance.
-
Polish News Registration and Interests of Cannabis Businesses
-
Permissions for Cannabis Sales in Poland
-
Authorization for Importing or Manufacturing Medical Products
-
Permission for Manufacturing or Importing Medical Products
-
Certificate of Good Manufacturing Practices (GMP)
-
Registration of Medical Products in Poland